查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086130

嗜睡症治療市場：2026-2032年全球市場預測（依藥物類別、疾病類型、年齡層、劑型及通路分類）

Narcolepsy Treatment Market by Drug Class, Disorder Type, Age Group, Dosage Form, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，嗜睡症治療市場將成長至 53.9 億美元，複合年成長率為 8.00%。

主要市場統計數據
基準年 2025 31.4億美元
預計年份：2026年 33.9億美元
預測年份 2032 53.9億美元
複合年成長率 (%) 8.00%

嗜睡症治療市場概覽

發作性睡病的治療正從症狀控制轉向精準睡眠醫學，採用的照護模式著重於白天過度嗜睡、猝倒、夜間睡眠障礙、入睡幻覺、睡眠癱瘓以及長期功能障礙。臨床上確診的發作性睡病通常分為「1型」和「2型」。 1型發作性睡病伴隨猝倒和下視丘泌素缺乏；2型發作性睡病通常不伴隨猝倒。

嗜睡症治療前景的變革性變化

隨著臨床醫生從廣泛使用興奮劑的治療方法轉向以實證醫學為基礎的標靶治療，發作性睡病的治療格局正在發生重大變化。羥丁酸鈉、羥丁酸氫鈉、索利安非托和匹曲桑等藥物的核准和上市，拓展了治療白天過度嗜睡和猝倒的臨床選擇，同時也加劇了藥物在安全性、給藥便利性、藥物交互作用以及患者報告療效等方面的競爭。

人工智慧（AI）的累積影響

人工智慧 (AI) 正成為發作性睡病治療整個價值鏈中一股切實的驅動力。利用人工智慧分析多睡眠多項生理檢查、多次睡眠潛伏期測試、腕動計、穿戴式睡眠數據和電子健康記錄 (EHR) 等數據，可以幫助識別持續性白天過度嗜睡的患者，減少診斷障礙，並促進早期轉診至睡眠專家。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

北美憑藉其完善的睡眠醫學基礎設施、專業的藥房網路、較高的認知度、完善的患者支持體係以及能夠儘早獲得FDA批准的品牌藥物，仍然是發作性睡病治療領域的領先地區。歐洲受益於國家醫療體系、歐洲食品藥物管理局管理局（EMA）的監管、臨床指南的採納以及對嚴格的藥物安全監測的期望，儘管各國的報銷途徑和醫療技術評估要求有所不同。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協地區，醫療保健投資的增加、都市區睡眠診所的建立以及數位醫療的普及，正促使睡眠障礙的早期發現。然而，專科醫生的短缺和保險報銷制度的不完善仍然是患者持續獲得發作性睡病治療的障礙。海灣合作理事會（GCC）國家重視先進的醫院和專業的醫療保健，對於高階發作性睡病藥物、醫生培訓、診斷夥伴關係以及創新藥物的規範進口管道而言，都是極具吸引力的市場。

對主要嗜睡症治療市場關鍵國家的深入分析。

美國是發作性睡病治療領域最具影響力的市場，這得益於其獲得FDA批准的品牌療法、專業的藥品分銷網路、完善的藥品監管系統、支付方管理以及強大的患者支持體系。在加拿大，重點在於循證保險報銷、專家主導的處方以及省級處方藥清單的評估。與此同時，墨西哥和巴西的認知度正在不斷提高，但仍面臨著許多挑戰，例如經濟負擔、診斷標準不統一以及獲取高度專業化藥物的途徑有限。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，例如減少鈉攝取、簡化給藥方式、改善夜間睡眠、減輕猝倒負擔、維持清醒狀態以及可衡量的功能性結果。打入市場策略應以真實世界數據為支撐，這些數據應證明藥物依從性、安全性、生活品質、生產力和醫療保健使用量的改善。

調查方法

本執行摘要採用系統的二手資料調查方法編寫，重點關注檢驗的公開資訊來源，包括監管資料庫、臨床指南、同行評審文獻、藥物安全監測資源以及經認可的醫療保健政策相關資料。分析內容涵蓋已通過核准的療法、臨床應用模式、診斷路徑、報銷趨勢、安全要求以及當地醫療保健基礎設施。

結論

隨著創新、診斷技術的進步以及以患者為中心的護理模式重塑治療決策，嗜睡症治療市場正在不斷發展。現有藥物和新興藥物在療效、安全性、便利性、鈉暴露、濫用風險管理和長期價值等方面競爭，而數位化工具和人工智慧正在提升早期識別和支持患者的能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 嗜睡症治療市場：依藥物類別分類

  • 抗憂鬱症
  • Orexin受體促效劑
  • 氧化鈉
  • 興奮劑

第8章：嗜睡症治療市場：依疾病類型分類

  • 1 型嗜睡症
  • 發作性睡病 2 型

第9章：嗜睡症治療市場：依年齡層分類

  • 成人
  • 老年人
  • 兒童

第10章：嗜睡症治療市場：依劑型分類

  • 藥片
  • 膠囊
  • 口服液體藥物

第11章 嗜睡症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 嗜睡症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：嗜睡症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 嗜睡症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Alkermes plc
  • Amneal Pharmaceuticals, Inc.
  • Arena Pharmaceuticals, Inc.
  • Avadel Pharmaceuticals plc
  • Axsome Therapeutics, Inc.
  • Azurity Pharmaceuticals, Inc.
  • Bioprojet Pharma SARL
  • Centessa Pharmaceuticals plc
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Harmony Biosciences Holdings, Inc.
  • Hikma Pharmaceuticals plc
  • Jazz Pharmaceuticals plc
  • Lupin Limited
  • NLS Pharmaceutics Ltd.
  • Novartis AG
  • Shionogi & Co., Ltd.
  • Sunovion Pharmaceuticals Inc.
  • Suven Life Sciences Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theranexus SA
  • Torrent Pharmaceuticals Limited
  • Zevra Therapeutics, Inc.
Product Code: MRR-036C5CF3B447

The Narcolepsy Treatment Market is projected to grow by USD 5.39 billion at a CAGR of 8.00% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.14 billion
Estimated Year [2026] USD 3.39 billion
Forecast Year [2032] USD 5.39 billion
CAGR (%) 8.00%

Narcolepsy Treatment Market Introduction

Narcolepsy treatment is moving from symptom control toward precision sleep medicine, with care models focused on excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, hypnagogic hallucinations, sleep paralysis, and long-term functional impairment. Clinically recognized narcolepsy is commonly categorized as type 1, associated with cataplexy and hypocretin deficiency, and type 2, generally without cataplexy.

The market is shaped by proven therapies such as oxybate formulations, wake-promoting agents, stimulants, selective histamine H3 receptor inverse agonists, and antidepressants used for cataplexy management. Growth is supported by higher diagnosis rates, improved sleep-lab access, expanded telehealth pathways, and the need for safer, longer-acting, lower-sodium, and adherence-friendly treatment options aligned with evidence-based sleep medicine standards.

Transformative Shifts in the Narcolepsy Treatment Landscape

The narcolepsy treatment landscape is undergoing a meaningful shift as clinicians move beyond broad stimulant-based management toward targeted, evidence-led regimens. The approval and adoption of therapies such as sodium oxybate, low-sodium oxybate, solriamfetol, and pitolisant have broadened clinical options for excessive daytime sleepiness and cataplexy while increasing competition around safety, dosing convenience, drug interaction profiles, and patient-reported outcomes.

Transformative change is also occurring in diagnosis and care delivery. Long diagnostic delays remain documented in narcolepsy, often spanning several years, which is driving investment in sleep-specialist networks, digital screening tools, validated sleep questionnaires, and patient education. Payers are increasingly evaluating real-world evidence, adherence, sodium burden, abuse potential, controlled-substance requirements, and total cost of care when determining access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across the narcolepsy treatment value chain. AI-assisted analysis of polysomnography, multiple sleep latency testing, actigraphy, wearable sleep data, and electronic health records can help identify patients with persistent excessive daytime sleepiness, reduce diagnostic friction, and support earlier referral to sleep specialists.

For drug developers and providers, AI strengthens clinical trial design, patient stratification, pharmacovigilance signal detection, adherence monitoring, and real-world outcomes assessment. Its cumulative impact is strongest where algorithms are clinically validated, explainable, privacy-compliant, and integrated with physician oversight, because narcolepsy diagnosis still depends on structured clinical history, objective sleep testing, and exclusion of other sleep disorders such as obstructive sleep apnea, insufficient sleep syndrome, and circadian rhythm disorders.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains a leading region for narcolepsy treatment because of established sleep medicine infrastructure, specialty pharmacy networks, favorable awareness, patient advocacy, and early access to branded therapies approved by the U.S. Food and Drug Administration. Europe benefits from national health systems, European Medicines Agency oversight, clinical guideline adoption, and strong pharmacovigilance expectations, although reimbursement pathways and health technology assessment requirements differ across countries.

Asia-Pacific is gaining strategic relevance as China, Japan, India, South Korea, and Australia expand sleep disorder diagnosis, specialist access, and neurology-focused care. Japan has long-standing sleep medicine expertise, while China and India present substantial underdiagnosis challenges linked to uneven access to sleep laboratories and trained specialists. Latin America shows improving awareness but faces inconsistent access to objective sleep testing and specialty medicines. The Middle East is supported by premium healthcare investment in GCC markets and growing demand for advanced neurology and sleep services, while Africa remains constrained by limited diagnostic capacity, workforce shortages, and affordability barriers, creating opportunities for education, screening, and scalable care models.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Across ASEAN, rising healthcare investment, urban sleep-clinic development, and digital health adoption are improving the identification of sleep disorders, although specialist shortages and variable reimbursement remain barriers to consistent narcolepsy treatment access. GCC countries are prioritizing advanced hospitals and specialty care, making them attractive for premium narcolepsy therapies, physician training, diagnostic partnerships, and regulated import pathways for innovative medicines.

The European Union provides a structured environment for evidence-based prescribing, centralized regulatory review, health technology assessment, and post-marketing safety surveillance. BRICS markets combine large patient pools with variable reimbursement maturity and uneven sleep-laboratory availability, creating demand for cost-sensitive access strategies and clinician education. G7 markets lead in therapeutic innovation, reimbursement scrutiny, pharmacovigilance, and real-world evidence generation, while NATO countries largely overlap with advanced healthcare systems where supply continuity, controlled-substance compliance, cybersecurity, and regulatory resilience influence market access.

Key Country Insights Across Major Narcolepsy Treatment Markets

The United States is the most influential narcolepsy treatment market due to FDA-approved branded therapies, specialty distribution, controlled-substance monitoring, payer management, and strong patient advocacy. Canada emphasizes evidence-based reimbursement, specialist-led prescribing, and provincial formulary evaluation, while Mexico and Brazil are expanding awareness but continue to face affordability, uneven diagnosis, and limited access to advanced specialty medicines.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong clinical capability but differ in health technology assessment, reimbursement timelines, and regional prescribing pathways. Russia presents access complexity linked to regulatory, supply, and geopolitical factors. In Asia-Pacific, China and India offer large underdiagnosed populations and growing neurology infrastructure, Japan has established sleep medicine expertise and recognized narcolepsy research activity, South Korea combines digital healthcare capacity with specialty care, and Australia benefits from structured clinical pathways, public-private healthcare coverage, and high awareness of sleep disorders.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value, including lower sodium exposure, simplified dosing, improved nighttime sleep, reduced cataplexy burden, durable wakefulness, and measurable functional outcomes. Market access strategies should be supported by real-world evidence demonstrating adherence, safety, quality-of-life improvement, productivity gains, and reduced healthcare utilization.

Organizations should also invest in diagnostic partnerships with sleep centers, neurologists, psychiatrists, pulmonologists, pediatric specialists, and primary care networks to shorten the patient journey. Scalable education for clinicians and patients, responsible AI-enabled screening, pharmacovigilance excellence, controlled-substance stewardship, and region-specific pricing models will be essential to expand access without compromising clinical standards.

Research Methodology

This executive summary is developed using a structured secondary-research methodology focused on verified public sources, including regulatory databases, clinical guidelines, peer-reviewed literature, pharmacovigilance resources, and recognized healthcare policy references. The analysis considers approved therapies, clinical use patterns, diagnosis pathways, reimbursement dynamics, safety requirements, and regional healthcare infrastructure.

Insights are triangulated across epidemiology, treatment availability, policy environments, clinical practice guidance, and market access indicators. No unverified market-size, market-share, or growth-rate claims are used; instead, the summary emphasizes evidence-backed industry drivers, barriers, and strategic implications relevant to narcolepsy treatment stakeholders.

Conclusion

The narcolepsy treatment market is advancing as innovation, diagnosis improvement, and patient-centered care reshape therapeutic decision-making. Established and emerging medicines are competing on efficacy, safety, convenience, sodium exposure, abuse-risk management, and long-term value, while digital tools and AI are improving the ability to identify and support patients earlier.

Future leadership will depend on credible evidence, equitable access, regional execution, and collaboration across sleep medicine ecosystems. Organizations that align product differentiation with diagnostic enablement, payer expectations, regulatory requirements, and patient outcomes will be best positioned in the evolving narcolepsy treatment landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Narcolepsy Treatment Market, by Drug Class

  • 7.1. Antidepressants
  • 7.2. Orexin Receptor Agonists
  • 7.3. Sodium Oxybate
  • 7.4. Stimulants

8. Narcolepsy Treatment Market, by Disorder Type

  • 8.1. Narcolepsy Type 1
  • 8.2. Narcolepsy Type 2

9. Narcolepsy Treatment Market, by Age Group

  • 9.1. Adults
  • 9.2. Geriatrics
  • 9.3. Pediatrics

10. Narcolepsy Treatment Market, by Dosage Form

  • 10.1. Tablets
  • 10.2. Capsules
  • 10.3. Oral Solutions

11. Narcolepsy Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Narcolepsy Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Narcolepsy Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Narcolepsy Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Alkermes plc
  • 16.2. Amneal Pharmaceuticals, Inc.
  • 16.3. Arena Pharmaceuticals, Inc.
  • 16.4. Avadel Pharmaceuticals plc
  • 16.5. Axsome Therapeutics, Inc.
  • 16.6. Azurity Pharmaceuticals, Inc.
  • 16.7. Bioprojet Pharma S.A.R.L.
  • 16.8. Centessa Pharmaceuticals plc
  • 16.9. Eli Lilly and Company
  • 16.10. H. Lundbeck A/S
  • 16.11. Harmony Biosciences Holdings, Inc.
  • 16.12. Hikma Pharmaceuticals plc
  • 16.13. Jazz Pharmaceuticals plc
  • 16.14. Lupin Limited
  • 16.15. NLS Pharmaceutics Ltd.
  • 16.16. Novartis AG
  • 16.17. Shionogi & Co., Ltd.
  • 16.18. Sunovion Pharmaceuticals Inc.
  • 16.19. Suven Life Sciences Limited
  • 16.20. Takeda Pharmaceutical Company Limited
  • 16.21. Teva Pharmaceutical Industries Ltd.
  • 16.22. Theranexus SA
  • 16.23. Torrent Pharmaceuticals Limited
  • 16.24. Zevra Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NARCOLEPSY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NARCOLEPSY TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NARCOLEPSY TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NARCOLEPSY TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NARCOLEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NARCOLEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OREXIN RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OREXIN RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OREXIN RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SODIUM OXYBATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SODIUM OXYBATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SODIUM OXYBATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STIMULANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STIMULANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STIMULANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NARCOLEPSY TYPE 1 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NARCOLEPSY TYPE 1 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NARCOLEPSY TYPE 1 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NARCOLEPSY TYPE 2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NARCOLEPSY TYPE 2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NARCOLEPSY TYPE 2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GCC NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 101. GCC NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. G7 NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. G7 NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. NATO NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. NATO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NARCOLEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. CANADA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 138. CANADA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. MEXICO NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. BRAZIL NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED KINGDOM NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. GERMANY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 168. FRANCE NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. RUSSIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ITALY NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. ITALY NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. SPAIN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. INDIA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. INDIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 210. AUSTRALIA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. SOUTH KOREA NARCOLEPSY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. SOUTH KOREA NARCOLEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. SOUTH KOREA NARCOLEPSY TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. SOUTH KOREA NARCOLEPSY TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. SOUTH KOREA NARCOLEPSY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 216. SOUTH KOREA NARCOLEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)